Fig. 2.

Increased myeloid-lineage leukocyte infiltration within CTX-treated patients. (A) CD14^hiCD11b⁺HLA-DR⁺ macrophages shown as a percent of total CD45⁺ cells as determined by flow cytometry. (B) Representative immunohistochemistry for CSF1R in tumors from either CTX-naïve (Upper) or CTX-treated (Lower) patients. Red arrows indicate cells displayed in enlarged insets. FcεR1α⁺CD117⁺CD11b⁻CD49d⁺ mast cells (C), CD15⁺CD11b⁺CD49d⁻ neutrophils (D), FcεR1α⁺CD117⁻CD11b⁻CD49d⁺ basophils (E), and CD11c⁺HLA-DR⁺CD14^lo/− (F) DCs shown as a percent of total CD45⁺ cells. N, nonadjacent normal; T, tumor.